Prestige Consumer Healthcare (PBH) Financials

$85.07 -0.05 (-0.06%)

As of 11:38 AM Eastern

Annual Income Statements for Prestige Consumer Healthcare

This table shows Prestige Consumer Healthcare's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	3/31/2015	3/31/2016	3/31/2017	3/31/2018	3/31/2019	3/31/2020	3/31/2021	3/31/2022	3/31/2023	3/31/2024	3/31/2025
Net Income / (Loss) Attributable to Common Shareholders	78	100	69	2,422	-36	142	165	205	-82	209	215
Consolidated Net Income / (Loss)	78	100	69	340	-36	142	165	205	-82	209	215
Net Income / (Loss) Continuing Operations	78	100	69	2,422	-36	142	165	205	-82	209	215
Total Pre-Tax Income	127	157	111	107	-38	191	204	262	-94	276	284
Total Operating Income	208	260	206	215	68	291	297	330	-22	342	337
Total Gross Profit	406	467	500	577	556	552	547	621	625	624	634
Total Revenue	715	806	882	3,124	976	963	943	1,087	1,128	1,125	1,138
Operating Revenue	710	803	882	1,041	976	963	943	1,087	1,128	1,125	1,138
Total Cost of Revenue	308	339	382	465	420	411	396	466	502	501	503
Operating Cost of Revenue	308	339	382	465	420	411	396	466	502	501	503
Total Operating Expenses	199	207	295	361	488	261	250	291	648	282	298
Selling, General & Admin Expense	81	72	89	85	90	89	83	107	107	106	108
Marketing Expense	100	111	128	147	143	147	141	157	145	153	156
Depreciation Expense	18	24	25	28	27	25	24	25	25	23	21
Impairment Charge	-	0.00	0.00	100	229	-	2.43	1.06	370	0.00	12
Total Other Income / (Expense), net	-80	-103	-95	-108	-106	-100	-93	-67	-72	-66	-53
Interest Expense	81	103	95	109	105	98	95	66	69	67	48
Other Income / (Expense), net	1.13	-	-0.03	0.39	-0.48	-1.63	1.37	-1.05	-2.34	0.76	-4.95
Income Tax Expense	49	57	41	-232	-2.26	49	39	57	-12	67	70
Basic Earnings per Share	$1.50	$1.89	$1.31	$6.40	($0.69)	$2.81	$3.28	$4.09	($1.65)	$4.21	$4.32
Weighted Average Basic Shares Outstanding	52.17M	52.75M	52.98M	53.10M	52.07M	50.72M	50.21M	50.26M	49.89M	49.76M	49.70M
Diluted Earnings per Share	$1.49	$1.88	$1.30	$6.34	($0.69)	$2.78	$3.25	$4.04	($1.65)	$4.17	$4.29
Weighted Average Diluted Shares Outstanding	52.67M	53.14M	53.36M	53.53M	52.07M	51.14M	50.61M	50.84M	49.89M	50.18M	50.08M
Weighted Average Basic & Diluted Shares Outstanding	52.20M	52.90M	53M	53.10M	51.90M	50.09M	49.91M	50.28M	49.69M	49.92M	49.41M

This table shows Prestige Consumer Healthcare's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Net Income / (Loss) Attributable to Common Shareholders	51	52	-241	53	54	53	49	49	54	61	50
Consolidated Net Income / (Loss)	51	52	-241	53	54	53	49	49	54	61	50
Net Income / (Loss) Continuing Operations	51	52	-241	53	54	53	49	49	54	61	50
Total Pre-Tax Income	67	68	-300	69	70	70	67	58	72	80	74
Total Operating Income	84	87	-281	85	88	87	82	72	84	92	88
Total Gross Profit	161	150	154	155	160	158	152	146	157	161	170
Total Revenue	289	276	286	279	286	283	277	267	284	290	297
Operating Revenue	289	276	286	279	286	283	277	267	284	290	297
Total Cost of Revenue	128	125	132	125	126	125	125	121	126	129	127
Operating Cost of Revenue	128	125	132	125	126	125	125	121	126	129	127
Total Operating Expenses	77	63	435	69	72	71	70	74	73	69	82
Selling, General & Admin Expense	26	27	28	28	26	26	26	29	26	26	27
Marketing Expense	44	30	31	36	40	39	38	39	41	38	37
Depreciation Expense	6.37	6.26	6.01	5.56	5.67	5.64	5.68	5.70	5.57	4.96	5.06
Total Other Income / (Expense), net	-18	-19	-19	-16	-18	-17	-15	-14	-13	-12	-14
Interest Expense	17	18	19	18	18	17	15	13	12	11	11
Other Income / (Expense), net	-0.81	-1.15	0.45	1.24	-0.23	-0.68	0.43	-0.50	-0.40	-0.35	-3.71
Income Tax Expense	16	16	-59	15	17	17	18	9.35	17	19	24
Basic Earnings per Share	$1.02	$1.05	($4.82)	$1.07	$1.08	$1.07	$0.99	$0.98	$1.10	$1.23	$1.01
Weighted Average Basic Shares Outstanding	49.80M	49.69M	49.89M	49.77M	49.69M	49.74M	49.76M	49.89M	49.65M	49.60M	49.70M
Diluted Earnings per Share	$1.02	$1.04	($4.80)	$1.06	$1.07	$1.06	$0.98	$0.98	$1.09	$1.22	$1.00
Weighted Average Diluted Shares Outstanding	50.27M	50.19M	49.89M	50.20M	50.08M	50.13M	50.18M	50.27M	50.00M	49.99M	50.08M
Weighted Average Basic & Diluted Shares Outstanding	49.53M	49.69M	49.69M	49.54M	49.62M	49.65M	49.92M	49.56M	49.41M	49.54M	49.41M

This table details how cash moves in and out of Prestige Consumer Healthcare's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	3/31/2015	3/31/2016	3/31/2017	3/31/2018	3/31/2019	3/31/2020	3/31/2021	3/31/2022	3/31/2023	3/31/2024	3/31/2025
Net Change in Cash & Equivalents	-7.01	5.91	15	-9.31	-5.02	67	-62	-5.12	31	-12	51
Net Cash From Operating Activities	156	176	149	210	189	217	236	260	230	249	252
Net Cash From Continuing Operating Activities	156	176	149	210	189	217	236	260	230	249	252
Net Income / (Loss) Continuing Operations	78	100	69	340	-36	142	165	205	-82	209	215
Consolidated Net Income / (Loss)	78	100	69	340	-36	142	165	205	-82	209	215
Depreciation Expense	18	24	26	33	32	29	30	32	33	31	30
Amortization Expense	8.82	8.99	8.63	6.74	5.92	3.81	4.98	4.23	4.36	5.24	1.75
Non-Cash Adjustments To Reconcile Net Income	6.89	20	64	115	236	11	16	13	383	13	25
Changes in Operating Assets and Liabilities, net	45	24	-19	-285	-49	31	20	5.48	-108	-9.63	-20
Net Cash From Investing Activities	-805	-223	-695	-12	55	-17	-22	-257	-12	-20	-17
Net Cash From Continuing Investing Activities	-805	-223	-695	-12	55	-17	-22	-257	-12	-20	-17
Purchase of Property, Plant & Equipment	-6.10	-3.57	-2.98	-13	-10	-15	-22	-9.64	-7.78	-9.55	-8.22
Other Investing Activities, net	-	-	-	0.97	0.00	0.75	0.00	-247	-	-11	-9.23
Net Cash From Financing Activities	643	52	561	-209	-249	-131	-279	-7.57	-186	-241	-182
Net Cash From Continuing Financing Activities	643	52	561	-209	-249	-131	-279	-7.57	-186	-241	-182
Repayment of Debt	-205	-498	-979	-490	-245	-575	-883	-691	-155	-226	-135
Repurchase of Common Equity	-	-	0.00	0.00	-50	-57	-12	0.00	-50	-25	-52
Issuance of Debt	845	545	1,537	280	45	500	615	682	20	0.00	0.00
Other Financing Activities, net	3.18	4.47	2.60	0.55	0.65	-0.13	0.17	1.54	-0.85	9.75	4.43
Effect of Exchange Rate Changes	-1.28	0.50	-	1.10	-0.41	-1.89	3.60	-	-0.98	-	-0.57
Cash Interest Paid	70	79	85	99	98	92	80	61	54	63	48
Cash Income Taxes Paid	12	15	48	24	33	31	34	47	41	60	52

This table details how cash moves in and out of Prestige Consumer Healthcare's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Net Change in Cash & Equivalents	6.57	44	-28	-3.91	5.49	3.55	-17	-12	17	-0.67	47
Net Cash From Operating Activities	58	55	59	48	62	71	67	55	70	65	62
Net Cash From Continuing Operating Activities	58	55	59	48	62	71	67	55	70	65	62
Net Income / (Loss) Continuing Operations	51	52	-241	53	54	53	49	49	54	61	50
Consolidated Net Income / (Loss)	51	52	-241	53	54	53	49	49	54	61	50
Depreciation Expense	8.25	8.13	7.86	7.54	7.64	7.65	7.84	8.12	7.93	6.87	7.25
Amortization Expense	0.97	0.82	1.75	0.98	1.32	1.42	1.51	0.45	0.43	0.43	0.44
Non-Cash Adjustments To Reconcile Net Income	3.44	2.48	373	3.65	3.70	7.66	3.55	3.25	2.05	2.81	17
Changes in Operating Assets and Liabilities, net	-6.14	-8.44	-83	-17	-3.76	1.70	4.54	-6.12	5.02	-6.05	-13
Net Cash From Investing Activities	-2.38	-1.80	-6.36	2.32	-2.93	-4.50	-15	-2.13	-2.03	-9.82	-3.48
Net Cash From Continuing Investing Activities	-2.38	-1.80	-6.36	2.32	-2.93	-4.50	-15	-2.13	-2.03	-9.82	-3.48
Purchase of Property, Plant & Equipment	-2.38	-1.80	-2.56	-1.48	-2.93	-2.00	-3.14	-1.15	-2.03	-1.57	-3.48
Net Cash From Financing Activities	-48	-10	-80	-54	-54	-65	-68	-66	-51	-54	-11
Net Cash From Continuing Financing Activities	-48	-10	-80	-54	-54	-65	-68	-66	-51	-54	-11
Repurchase of Common Equity	-12	-	-	-25	-	-	-	-26	-12	-2.40	-11
Other Financing Activities, net	-0.68	4.98	-0.50	0.82	1.45	0.93	6.56	-4.55	0.62	8.54	-0.18
Effect of Exchange Rate Changes	-	-	-	-0.14	-0.49	1.42	-	-	-	-2.08	0.13
Cash Interest Paid	15	18	18	18	16	16	14	14	12	12	10
Cash Income Taxes Paid	14	12	13	12	13	13	21	3.66	15	15	19

This table presents Prestige Consumer Healthcare's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	3/31/2015	3/31/2016	3/31/2017	3/31/2018	3/31/2019	3/31/2020	3/31/2021	3/31/2022	3/31/2023	3/31/2024	3/31/2025
Total Assets	2,642	2,949	3,911	3,761	3,441	3,514	3,429	3,671	3,354	3,318	3,402
Total Current Assets	202	249	334	303	301	366	270	293	392	375	448
Cash & Equivalents	21	27	42	33	28	95	32	27	58	46	98
Accounts Receivable	88	95	137	141	149	151	115	139	167	177	194
Inventories, net	74	91	116	119	120	116	115	120	162	139	148
Prepaid Expenses	10	25	40	12	4.74	4.35	7.90	6.41	4.12	13	8.44
Plant, Property, & Equipment, net	14	16	51	53	51	56	70	71	70	77	75
Total Noncurrent Assets	2,427	2,684	3,526	3,405	3,089	3,092	3,089	3,306	2,892	2,867	2,879
Noncurrent Note & Lease Receivables	-	-	-	-	0.00	5.84	8.99	6.86	4.20	1.54	25
Goodwill	291	360	615	620	579	575	578	579	528	528	527
Intangible Assets	2,135	2,323	2,904	2,781	2,507	2,479	2,476	2,697	2,342	2,321	2,295
Other Noncurrent Operating Assets	1.17	1.32	7.45	3.57	3.13	32	27	24	18	17	32
Total Liabilities & Shareholders' Equity	2,642	2,949	3,911	3,761	3,441	3,514	3,429	3,671	3,354	3,318	3,402
Total Liabilities	2,014	2,204	3,089	2,582	2,345	2,343	2,071	2,093	1,907	1,663	1,567
Total Current Liabilities	99	107	162	123	127	150	122	143	161	117	107
Accounts Payable	46	38	70	61	57	62	46	56	63	39	19
Accrued Expenses	41	60	84	52	61	71	61	74	73	56	63
Dividends Payable	12	8.66	8.13	9.71	9.76	9.91	6.31	4.44	16	16	16
Other Current Liabilities	-	-	-	-	0.00	6.83	8.45	9.11	9.76	6.15	8.54
Total Noncurrent Liabilities	1,915	2,098	2,927	2,459	2,218	2,193	1,949	1,950	1,746	1,546	1,461
Long-Term Debt	1,561	1,625	2,194	1,993	1,799	1,730	1,480	1,477	1,346	1,126	992
Capital Lease Obligations	-	-	-	-	0.00	30	27	21	12	7.70	43
Noncurrent Deferred & Payable Income Tax Liabilities	352	470	715	443	400	408	434	445	380	404	420
Other Noncurrent Operating Liabilities	2.46	2.84	18	23	20	25	8.61	7.48	8.17	9.19	5.39
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	628	744	823	1,179	1,096	1,171	1,358	1,578	1,447	1,655	1,835
Total Preferred & Common Equity	628	744	823	1,179	1,096	1,171	1,358	1,578	1,447	1,655	1,835
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	628	744	823	1,179	1,096	1,171	1,358	1,578	1,447	1,655	1,835
Common Stock	427	446	459	469	480	489	500	516	536	568	594
Retained Earnings	227	327	397	736	702	844	1,009	1,214	1,132	1,341	1,556
Treasury Stock	-3.48	-5.16	-6.59	-7.67	-60	-118	-131	-134	-189	-220	-277
Accumulated Other Comprehensive Income / (Loss)	-23	-24	-26	-19	-26	-44	-20	-19	-32	-34	-38

This table presents Prestige Consumer Healthcare's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025
Period end date	12/31/2021	6/30/2022	9/30/2022	12/31/2022	6/30/2023	9/30/2023	12/31/2023	6/30/2024	9/30/2024	12/31/2024
Total Assets	3,659	3,682	3,679	3,750	3,346	3,333	3,340	3,308	3,317	3,329
Total Current Assets	275	325	337	409	392	388	394	369	381	377
Cash & Equivalents	21	36	42	86	55	60	64	34	52	51
Accounts Receivable	134	145	146	157	158	158	174	172	164	167
Inventories, net	106	134	141	159	170	161	149	152	156	152
Prepaid Expenses	14	9.53	7.71	6.89	9.38	8.39	7.25	11	9.40	7.50
Plant, Property, & Equipment, net	70	70	70	70	70	71	70	75	75	74
Total Noncurrent Assets	3,285	3,287	3,272	3,271	2,884	2,874	2,876	2,863	2,861	2,879
Noncurrent Note & Lease Receivables	-	6.19	5.53	4.86	3.54	2.87	2.21	0.88	0.21	4.94
Goodwill	579	577	576	577	527	527	528	528	529	527
Intangible Assets	2,704	2,683	2,671	2,670	2,336	2,328	2,329	2,318	2,317	2,311
Other Noncurrent Operating Assets	2.89	22	20	20	17	16	17	16	15	36
Total Liabilities & Shareholders' Equity	3,659	3,682	3,679	3,750	3,346	3,333	3,340	3,308	3,317	3,329
Total Liabilities	2,141	2,097	2,059	2,063	1,865	1,797	1,739	1,627	1,585	1,541
Total Current Liabilities	135	155	152	160	147	130	127	114	107	103
Accounts Payable	40	58	56	64	58	44	39	40	31	20
Accrued Expenses	71	73	71	71	65	60	65	55	57	61
Dividends Payable	15	15	16	15	15	16	15	15	16	15
Other Current Liabilities	-	9.32	9.44	9.67	9.46	9.61	7.84	4.45	2.65	6.92
Total Noncurrent Liabilities	453	1,942	1,906	1,903	1,718	1,667	1,612	1,513	1,478	1,439
Long-Term Debt	-	1,472	1,438	1,424	1,317	1,263	1,199	1,091	1,052	992
Capital Lease Obligations	-	3.80	3.09	14	9.16	0.22	6.33	7.20	0.13	28
Noncurrent Deferred & Payable Income Tax Liabilities	445	443	443	456	384	388	397	409	415	413
Other Noncurrent Operating Liabilities	8.43	23	22	8.87	8.18	16	8.92	5.14	12	5.03
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	1,518	1,585	1,620	1,687	1,480	1,536	1,601	1,681	1,732	1,788
Total Preferred & Common Equity	1,518	1,585	1,620	1,687	1,480	1,536	1,601	1,681	1,732	1,788
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	1,518	1,585	1,620	1,687	1,480	1,536	1,601	1,681	1,732	1,788
Common Stock	513	521	525	533	547	553	557	573	577	589
Retained Earnings	1,162	1,269	1,320	1,372	1,185	1,239	1,292	1,390	1,445	1,506
Treasury Stock	-134	-177	-189	-189	-220	-220	-220	-252	-263	-266
Accumulated Other Comprehensive Income / (Loss)	-23	-29	-36	-29	-32	-36	-29	-31	-27	-40

This table displays calculated financial ratios and metrics derived from Prestige Consumer Healthcare's official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	3/31/2015	3/31/2016	3/31/2017	3/31/2018	3/31/2019	3/31/2020	3/31/2021	3/31/2022	3/31/2023	3/31/2024	3/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	19.63%	12.82%	9.40%	254.12%	-68.76%	-1.31%	-2.04%	15.21%	3.76%	-0.21%	1.10%
EBITDA Growth	10.65%	24.54%	-18.07%	6.66%	-59.10%	207.78%	3.59%	9.37%	-96.65%	2,997.73%	-4.05%
EBIT Growth	10.64%	24.74%	-21.01%	4.99%	-68.95%	331.96%	3.19%	10.07%	-107.53%	1,486.55%	-3.31%
NOPAT Growth	-5.33%	29.83%	-22.19%	430.74%	-93.08%	358.64%	10.72%	7.59%	-106.08%	1,755.14%	-2.07%
Net Income Growth	7.77%	27.66%	-30.54%	389.33%	-110.54%	497.43%	15.74%	24.71%	-140.07%	354.34%	2.52%
EPS Growth	7.19%	26.17%	-30.85%	387.69%	-110.88%	502.90%	16.91%	24.31%	-140.84%	352.73%	2.88%
Operating Cash Flow Growth	40.04%	12.83%	-15.68%	41.32%	-9.91%	14.71%	8.51%	10.32%	-11.62%	8.36%	1.04%
Free Cash Flow Firm Growth	-658.47%	98.94%	-8,194.20%	202.86%	-38.25%	-22.51%	-0.02%	-81.99%	516.93%	-4.14%	-15.06%
Invested Capital Growth	47.36%	7.87%	26.86%	5.57%	-8.64%	-1.07%	-0.26%	7.53%	-9.52%	-0.14%	1.11%
Revenue Q/Q Growth	7.04%	2.26%	3.86%	204.47%	-72.56%	106.12%	-1.69%	2.76%	1.71%	-0.78%	1.75%
EBITDA Q/Q Growth	10.04%	1.77%	-4.90%	-22.74%	-55.68%	205.15%	2.55%	1.73%	-96.69%	2,235.94%	0.13%
EBIT Q/Q Growth	9.11%	1.57%	-5.61%	-25.99%	-66.06%	300.47%	2.66%	1.62%	-107.44%	1,820.83%	0.65%
NOPAT Q/Q Growth	10.32%	0.02%	-4.57%	7.10%	-66.90%	327.49%	6.28%	2.25%	-105.92%	1,890.46%	-0.17%
Net Income Q/Q Growth	11.02%	-8.96%	-3.94%	-13.01%	-156.12%	686.53%	5.27%	8.78%	-139.13%	359.50%	0.31%
EPS Q/Q Growth	12.03%	-9.62%	-3.70%	-13.03%	-156.10%	795.00%	5.86%	8.60%	-139.57%	359.01%	0.47%
Operating Cash Flow Q/Q Growth	15.86%	-6.50%	-17.86%	28.75%	-1.86%	2.49%	1.27%	1.58%	-1.77%	3.29%	-1.97%
Free Cash Flow Firm Q/Q Growth	15.65%	-102.21%	-589.49%	218.73%	2.22%	-8.82%	4.24%	13.03%	7.14%	-6.41%	-6.61%
Invested Capital Q/Q Growth	-2.56%	10.46%	38.05%	-2.64%	-6.13%	0.08%	0.22%	0.23%	-9.57%	0.00%	0.56%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	56.84%	57.95%	56.72%	18.46%	56.94%	57.34%	58.03%	57.11%	55.45%	55.49%	55.76%
EBITDA Margin	32.92%	36.34%	27.21%	8.20%	10.73%	33.47%	35.40%	33.60%	1.09%	33.69%	31.97%
Operating Margin	29.04%	32.29%	23.31%	6.90%	6.92%	30.23%	31.53%	30.36%	-1.99%	30.43%	29.60%
EBIT Margin	29.20%	32.29%	23.31%	6.91%	6.87%	30.07%	31.67%	30.26%	-2.19%	30.50%	29.16%
Profit (Net Income) Margin	10.95%	12.39%	7.87%	10.87%	-3.67%	14.77%	17.46%	18.90%	-7.30%	18.60%	18.86%
Tax Burden Percent	61.40%	63.56%	62.60%	317.10%	94.07%	74.43%	80.68%	78.25%	87.64%	75.84%	75.51%
Interest Burden Percent	61.07%	60.38%	53.91%	49.61%	-56.78%	66.02%	68.32%	79.81%	379.44%	80.43%	85.65%
Effective Tax Rate	38.60%	36.44%	37.40%	-217.10%	0.00%	25.57%	19.32%	21.75%	0.00%	24.16%	24.49%
Return on Invested Capital (ROIC)	6.97%	7.30%	4.83%	22.29%	1.57%	7.57%	8.44%	8.77%	-0.54%	9.41%	9.17%
ROIC Less NNEP Spread (ROIC-NNEP)	2.98%	3.15%	1.68%	5.64%	-2.86%	3.27%	3.67%	5.19%	-5.32%	5.24%	5.31%
Return on Net Nonoperating Assets (RNNOA)	6.18%	7.26%	4.03%	11.65%	-4.72%	4.98%	4.58%	5.23%	-4.90%	4.09%	3.13%
Return on Equity (ROE)	13.14%	14.56%	8.86%	33.94%	-3.15%	12.55%	13.02%	13.99%	-5.44%	13.50%	12.30%
Cash Return on Invested Capital (CROIC)	-31.33%	-0.27%	-18.85%	16.87%	10.60%	8.65%	8.70%	1.51%	9.45%	9.55%	8.07%
Operating Return on Assets (OROA)	9.41%	9.31%	5.99%	5.63%	1.86%	8.33%	8.61%	9.26%	-0.70%	10.29%	9.87%
Return on Assets (ROA)	3.53%	3.57%	2.02%	8.85%	-0.99%	4.09%	4.74%	5.79%	-2.34%	6.28%	6.39%
Return on Common Equity (ROCE)	13.14%	14.56%	8.86%	33.94%	-3.15%	12.55%	13.02%	13.99%	-5.44%	13.50%	12.30%
Return on Equity Simple (ROE_SIMPLE)	12.47%	13.42%	8.44%	28.81%	-3.27%	12.15%	12.12%	13.02%	-5.69%	12.65%	11.70%
Net Operating Profit after Tax (NOPAT)	127	165	129	683	47	217	240	258	-16	260	254
NOPAT Margin	17.83%	20.52%	14.60%	21.87%	4.84%	22.50%	25.44%	23.75%	-1.39%	23.08%	22.35%
Net Nonoperating Expense Percent (NNEP)	3.99%	4.15%	3.15%	16.64%	4.43%	4.31%	4.77%	3.57%	4.78%	4.17%	3.86%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-	-	-	8.86%
Cost of Revenue to Revenue	43.16%	42.05%	43.28%	14.88%	43.06%	42.66%	41.97%	42.89%	44.55%	44.51%	44.24%
SG&A Expenses to Revenue	11.37%	8.98%	10.10%	2.73%	9.20%	9.25%	8.81%	9.89%	9.52%	9.43%	9.51%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	27.80%	25.66%	33.40%	11.56%	50.02%	27.11%	26.51%	26.75%	57.44%	25.06%	26.16%
Earnings before Interest and Taxes (EBIT)	209	260	206	216	67	290	299	329	-25	343	332
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	235	293	240	256	105	322	334	365	12	379	364
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.53	3.74	3.53	1.50	1.41	1.57	1.62	1.68	2.15	2.18	2.32
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	3.10	3.45	3.29	0.57	1.59	1.91	2.33	2.45	2.76	3.20	3.74
Price to Earnings (P/E)	28.30	27.84	41.86	0.73	0.00	12.96	13.35	12.94	0.00	17.21	19.84
Dividend Yield	0.00%	0.00%	0.00%	0.00%	1.59%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	3.53%	3.59%	2.39%	137.11%	0.00%	7.72%	7.49%	7.73%	0.00%	5.81%	5.04%
Enterprise Value to Invested Capital (EV/IC)	1.72	1.86	1.70	1.18	1.15	1.23	1.29	1.35	1.60	1.70	1.86
Enterprise Value to Revenue (EV/Rev)	5.25	5.43	5.73	1.19	3.40	3.64	3.89	3.80	3.91	4.17	4.57
Enterprise Value to EBITDA (EV/EBITDA)	15.96	14.95	21.07	14.56	31.70	10.89	11.00	11.30	360.42	12.37	14.29
Enterprise Value to EBIT (EV/EBIT)	17.99	16.83	24.59	17.26	49.54	12.12	12.29	12.55	0.00	13.66	15.66
Enterprise Value to NOPAT (EV/NOPAT)	29.46	26.47	39.28	5.45	70.27	16.19	15.30	15.99	0.00	18.06	20.43
Enterprise Value to Operating Cash Flow (EV/OCF)	24.03	24.84	34.01	17.74	17.54	16.16	15.58	15.88	19.20	18.84	20.66
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	7.21	10.40	14.18	14.84	92.66	16.05	17.80	23.22
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	2.49	2.18	2.67	1.69	1.64	1.50	1.11	0.95	0.94	0.68	0.56
Long-Term Debt to Equity	2.49	2.18	2.67	1.69	1.64	1.50	1.11	0.95	0.94	0.68	0.56
Financial Leverage	2.07	2.30	2.40	2.06	1.65	1.52	1.25	1.01	0.92	0.78	0.59
Leverage Ratio	3.73	4.08	4.38	3.83	3.17	3.07	2.75	2.42	2.32	2.15	1.93
Compound Leverage Factor	2.28	2.46	2.36	1.90	-1.80	2.03	1.88	1.93	8.81	1.73	1.65
Debt to Total Capital	71.33%	68.59%	72.73%	62.84%	62.14%	60.05%	52.58%	48.69%	48.40%	40.65%	36.08%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	71.33%	68.59%	72.73%	62.84%	62.14%	60.05%	52.58%	48.69%	48.40%	40.65%	36.08%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	28.67%	31.41%	27.27%	37.16%	37.86%	39.95%	47.42%	51.31%	51.60%	59.35%	63.92%
Debt to EBITDA	6.64	5.55	9.14	7.78	17.17	5.46	4.51	4.10	110.91	2.99	2.85
Net Debt to EBITDA	6.55	5.45	8.96	7.66	16.91	5.17	4.41	4.03	106.13	2.87	2.58
Long-Term Debt to EBITDA	6.64	5.55	9.14	7.78	17.17	5.46	4.51	4.10	110.91	2.99	2.85
Debt to NOPAT	12.25	9.82	17.04	2.92	38.06	8.12	6.28	5.80	-86.51	4.36	4.07
Net Debt to NOPAT	12.08	9.66	16.72	2.87	37.48	7.68	6.14	5.69	-82.78	4.19	3.69
Long-Term Debt to NOPAT	12.25	9.82	17.04	2.92	38.06	8.12	6.28	5.80	-86.51	4.36	4.07
Altman Z-Score	1.36	1.54	1.16	1.76	1.09	1.43	1.66	1.87	1.85	2.64	3.05
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.04	2.33	2.06	2.46	2.37	2.44	2.21	2.04	2.44	3.20	4.20
Quick Ratio	1.10	1.15	1.10	1.41	1.39	1.64	1.20	1.16	1.40	1.91	2.74
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-573	-6.06	-503	517	319	247	247	45	275	263	224
Operating Cash Flow to CapEx	0.00%	5,468.67%	5,140.80%	1,676.59%	1,806.15%	1,491.24%	1,059.24%	2,695.73%	2,951.13%	2,606.56%	3,058.31%
Free Cash Flow to Firm to Interest Expense	-7.05	-0.06	-5.29	4.74	3.04	2.52	2.61	0.67	3.97	3.92	4.70
Operating Cash Flow to Interest Expense	1.92	1.71	1.57	1.92	1.80	2.21	2.49	3.91	3.32	3.71	5.28
Operating Cash Flow Less CapEx to Interest Expense	1.97	1.68	1.54	1.81	1.70	2.06	2.25	3.77	3.21	3.56	5.11
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.32	0.29	0.26	0.81	0.27	0.28	0.27	0.31	0.32	0.34	0.34
Accounts Receivable Turnover	9.35	8.81	7.60	22.50	6.74	6.44	7.11	8.56	7.36	6.55	6.13
Inventory Turnover	4.42	4.10	3.69	3.97	3.52	3.48	3.43	3.96	3.56	3.33	3.51
Fixed Asset Turnover	61.23	55.06	26.67	60.56	18.81	17.97	14.97	15.38	15.92	15.32	15.06
Accounts Payable Turnover	6.53	8.03	7.04	7.06	7.13	6.91	7.31	9.16	8.48	9.85	17.38
Days Sales Outstanding (DSO)	39.05	41.45	48.00	16.22	54.18	56.72	51.30	42.65	49.58	55.75	59.52
Days Inventory Outstanding (DIO)	82.60	88.96	98.89	91.96	103.55	104.81	106.48	92.12	102.60	109.61	103.86
Days Payable Outstanding (DPO)	55.86	45.44	51.87	51.69	51.23	52.84	49.95	39.83	43.04	37.06	21.00
Cash Conversion Cycle (CCC)	65.79	84.97	95.02	56.50	106.50	108.69	107.83	94.94	109.13	128.30	142.38
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	2,180	2,351	2,983	3,149	2,877	2,846	2,838	3,052	2,762	2,758	2,788
Invested Capital Turnover	0.39	0.36	0.33	1.02	0.32	0.34	0.33	0.37	0.39	0.41	0.41
Increase / (Decrease) in Invested Capital	700	172	631	166	-272	-31	-7.44	214	-290	-3.73	31
Enterprise Value (EV)	3,754	4,380	5,057	3,727	3,320	3,509	3,672	4,128	4,411	4,690	5,197
Market Capitalization	2,214	2,782	2,905	1,766	1,549	1,844	2,198	2,658	3,112	3,603	4,259
Book Value per Share	$12.01	$14.11	$15.54	$22.22	$21.16	$23.30	$27.24	$31.43	$29.12	$33.34	$37.04
Tangible Book Value per Share	($34.39)	($36.75)	($50.94)	($41.90)	($38.42)	($37.47)	($34.00)	($33.83)	($28.63)	($24.03)	($19.94)
Total Capital	2,189	2,370	3,016	3,172	2,894	2,931	2,864	3,075	2,804	2,789	2,871
Total Debt	1,561	1,625	2,194	1,993	1,799	1,760	1,506	1,497	1,357	1,134	1,036
Total Long-Term Debt	1,561	1,625	2,194	1,993	1,799	1,760	1,506	1,497	1,357	1,134	1,036
Net Debt	1,540	1,598	2,152	1,960	1,771	1,665	1,474	1,470	1,299	1,087	938
Capital Expenditures (CapEx)	-3.90	3.22	2.89	13	10	15	22	9.64	7.78	9.55	8.22
Debt-free, Cash-free Net Working Capital (DFCFNWC)	81	115	131	148	146	121	115	123	173	212	244
Debt-free Net Working Capital (DFNWC)	103	142	172	180	174	216	148	150	231	258	342
Net Working Capital (NWC)	103	142	172	180	174	216	148	150	231	258	342
Net Nonoperating Expense (NNE)	49	66	59	344	83	74	75	53	67	50	40
Net Nonoperating Obligations (NNO)	1,552	1,607	2,160	1,970	1,781	1,675	1,480	1,474	1,315	1,103	954
Total Depreciation and Amortization (D&A)	27	33	34	40	38	33	35	36	37	36	32
Debt-free, Cash-free Net Working Capital to Revenue	11.38%	14.28%	14.80%	4.73%	15.01%	12.57%	12.23%	11.29%	15.30%	18.80%	21.43%
Debt-free Net Working Capital to Revenue	14.37%	17.65%	19.55%	5.77%	17.83%	22.41%	15.66%	13.79%	20.49%	22.93%	30.03%
Net Working Capital to Revenue	14.37%	17.65%	19.55%	5.77%	17.83%	22.41%	15.66%	13.79%	20.49%	22.93%	30.03%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$1.50	$1.89	$1.31	$6.40	($0.69)	$2.81	$3.28	$4.09	($1.65)	$4.21	$4.32
Adjusted Weighted Average Basic Shares Outstanding	52.17M	52.75M	52.98M	53.10M	52.07M	50.72M	50.21M	50.26M	49.89M	49.76M	49.70M
Adjusted Diluted Earnings per Share	$1.49	$1.88	$1.30	$6.34	($0.69)	$2.78	$3.25	$4.04	($1.65)	$4.17	$4.29
Adjusted Weighted Average Diluted Shares Outstanding	52.67M	53.14M	53.36M	53.53M	52.07M	51.14M	50.61M	50.84M	49.89M	50.18M	50.08M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	($0.69)	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	52.30M	52.76M	52.96M	53.07M	51.80M	50.09M	49.91M	50.28M	49.69M	49.92M	49.41M
Normalized Net Operating Profit after Tax (NOPAT)	127	165	129	221	208	217	242	259	243	260	264
Normalized NOPAT Margin	17.83%	20.52%	14.60%	7.07%	21.30%	22.50%	25.64%	23.83%	21.59%	23.08%	23.18%
Pre Tax Income Margin	17.84%	19.50%	12.57%	3.43%	-3.90%	19.85%	21.64%	24.15%	-8.33%	24.53%	24.98%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	2.57	2.52	2.17	1.98	0.64	2.94	3.16	4.95	-0.36	5.11	6.97
NOPAT to Interest Expense	1.57	1.60	1.36	6.26	0.45	2.20	2.54	3.89	-0.23	3.87	5.34
EBIT Less CapEx to Interest Expense	2.61	2.49	2.13	1.86	0.54	2.80	2.92	4.81	-0.47	4.97	6.79
NOPAT Less CapEx to Interest Expense	1.62	1.57	1.33	6.14	0.35	2.05	2.30	3.74	-0.34	3.72	5.17
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	-139.60%	39.87%	7.21%	0.00%	-60.75%	11.94%	24.00%

This table displays calculated financial ratios and metrics derived from Prestige Consumer Healthcare's official financial filings.

Metric	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	4.72%	0.38%	7.09%	0.81%	-1.02%	2.62%	-3.11%	-4.36%	-0.88%	2.68%	7.05%
EBITDA Growth	7.02%	3.41%	-411.98%	-0.46%	4.52%	0.25%	133.93%	-15.62%	-4.83%	3.88%	0.51%
EBIT Growth	7.05%	4.39%	-464.64%	0.28%	5.32%	0.13%	129.44%	-17.22%	-4.63%	6.34%	2.59%
NOPAT Growth	8.28%	5.00%	-397.36%	-2.63%	3.82%	-0.44%	130.68%	-8.38%	-4.66%	5.77%	-0.69%
Net Income Growth	12.57%	3.46%	-561.84%	-3.61%	4.97%	2.11%	120.56%	-7.90%	1.53%	15.05%	1.35%
EPS Growth	14.61%	5.05%	-570.59%	-2.75%	4.90%	1.92%	120.42%	-7.55%	1.87%	15.09%	2.04%
Operating Cash Flow Growth	-5.97%	-17.13%	-6.56%	-17.44%	8.55%	30.09%	13.43%	13.91%	11.75%	-8.93%	-7.56%
Free Cash Flow Firm Growth	138.88%	138.65%	163.60%	315.73%	429.85%	525.76%	-31.68%	-80.23%	-79.51%	-84.85%	-54.14%
Invested Capital Growth	-0.03%	0.28%	-9.52%	-9.00%	-9.22%	-9.69%	-0.14%	-0.24%	-0.26%	0.55%	1.11%
Revenue Q/Q Growth	4.41%	-4.75%	3.75%	-2.29%	2.51%	-1.25%	-2.03%	-3.56%	6.23%	2.30%	2.14%
EBITDA Q/Q Growth	-2.74%	2.36%	-385.25%	135.05%	2.13%	-1.82%	-3.45%	-12.85%	15.19%	7.16%	-6.57%
EBIT Q/Q Growth	-3.04%	2.95%	-426.09%	130.81%	1.84%	-2.13%	-4.14%	-13.36%	17.32%	9.13%	-7.52%
NOPAT Q/Q Growth	-4.69%	2.84%	-395.82%	133.58%	1.62%	-1.37%	-8.84%	0.28%	5.74%	9.42%	-14.41%
Net Income Q/Q Growth	-7.69%	1.82%	-563.04%	122.15%	0.53%	-0.96%	-6.76%	-0.79%	10.82%	12.24%	-17.87%
EPS Q/Q Growth	-6.42%	1.96%	-561.54%	122.08%	0.94%	-0.93%	-7.55%	0.00%	11.22%	11.93%	-18.03%
Operating Cash Flow Q/Q Growth	-1.21%	-4.52%	7.36%	-18.48%	29.89%	14.43%	-6.39%	-18.13%	27.43%	-6.75%	-4.98%
Free Cash Flow Firm Q/Q Growth	141.60%	-11.60%	62.06%	262.01%	2.17%	4.40%	-82.31%	4.74%	5.88%	-22.79%	-46.45%
Invested Capital Q/Q Growth	-0.19%	0.64%	-9.57%	0.19%	-0.44%	0.11%	0.00%	0.08%	-0.45%	0.92%	0.56%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	55.66%	54.59%	53.79%	55.38%	55.89%	55.86%	54.81%	54.66%	55.46%	55.47%	57.34%
EBITDA Margin	32.08%	34.47%	-94.77%	34.00%	33.87%	33.68%	33.19%	29.99%	32.53%	34.07%	31.16%
Operating Margin	29.17%	31.64%	-98.30%	30.50%	30.82%	30.71%	29.66%	26.97%	29.72%	31.68%	29.82%
EBIT Margin	28.89%	31.23%	-98.14%	30.94%	30.74%	30.47%	29.81%	26.78%	29.58%	31.55%	28.57%
Profit (Net Income) Margin	17.64%	18.86%	-84.15%	19.07%	18.71%	18.76%	17.86%	18.37%	19.16%	21.02%	16.91%
Tax Burden Percent	76.62%	76.27%	80.31%	77.53%	76.06%	76.24%	73.46%	84.00%	75.88%	76.14%	67.78%
Interest Burden Percent	79.68%	79.17%	106.76%	79.50%	80.00%	80.76%	81.52%	81.64%	85.37%	87.50%	87.30%
Effective Tax Rate	23.38%	23.73%	0.00%	22.47%	23.94%	23.76%	26.54%	16.00%	24.12%	23.86%	32.22%
Return on Invested Capital (ROIC)	8.16%	8.77%	-26.69%	9.20%	9.13%	9.14%	8.89%	9.13%	9.10%	9.75%	8.29%
ROIC Less NNEP Spread (ROIC-NNEP)	7.25%	7.77%	-29.84%	8.27%	8.10%	8.10%	7.98%	8.16%	8.24%	8.91%	7.34%
Return on Net Nonoperating Assets (RNNOA)	7.03%	7.02%	-27.51%	7.40%	6.76%	6.22%	6.22%	6.11%	5.64%	5.63%	4.32%
Return on Equity (ROE)	15.18%	15.79%	-54.21%	16.60%	15.89%	15.36%	15.11%	15.23%	14.74%	15.39%	12.62%
Cash Return on Invested Capital (CROIC)	8.66%	8.41%	9.45%	8.84%	9.17%	9.69%	9.55%	9.44%	9.38%	8.66%	8.07%
Operating Return on Assets (OROA)	8.70%	9.35%	-31.51%	9.95%	9.88%	9.75%	10.06%	8.96%	9.88%	10.58%	9.67%
Return on Assets (ROA)	5.31%	5.64%	-27.02%	6.13%	6.01%	6.00%	6.02%	6.15%	6.40%	7.05%	5.72%
Return on Common Equity (ROCE)	15.18%	15.79%	-54.21%	16.60%	15.89%	15.36%	15.11%	15.23%	14.74%	15.39%	12.62%
Return on Equity Simple (ROE_SIMPLE)	12.88%	12.47%	0.00%	-5.69%	-5.32%	-5.04%	0.00%	12.20%	11.89%	11.96%	0.00%
Net Operating Profit after Tax (NOPAT)	65	66	-197	66	67	66	60	61	64	70	60
NOPAT Margin	22.35%	24.13%	-68.81%	23.65%	23.44%	23.41%	21.79%	22.65%	22.55%	24.12%	20.21%
Net Nonoperating Expense Percent (NNEP)	0.91%	1.01%	3.14%	0.93%	1.03%	1.04%	0.90%	0.97%	0.86%	0.84%	0.95%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	2.36%	-	-	-	2.49%	2.09%
Cost of Revenue to Revenue	44.34%	45.41%	46.21%	44.62%	44.11%	44.14%	45.19%	45.34%	44.54%	44.53%	42.66%
SG&A Expenses to Revenue	9.14%	9.63%	9.68%	9.91%	9.08%	9.20%	9.55%	10.82%	9.19%	9.02%	9.12%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	26.49%	22.94%	152.08%	24.88%	25.07%	25.15%	25.15%	27.69%	25.74%	23.80%	27.51%
Earnings before Interest and Taxes (EBIT)	84	86	-281	86	88	86	83	72	84	92	85
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	93	95	-271	95	97	95	92	80	92	99	92
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.53	1.84	2.15	2.00	1.84	1.90	2.18	2.04	2.06	2.16	2.32
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	2.24	2.80	2.76	2.61	2.51	2.68	3.20	3.09	3.22	3.45	3.74
Price to Earnings (P/E)	11.89	14.74	0.00	0.00	0.00	0.00	17.21	16.75	17.35	18.03	19.84
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	8.41%	6.78%	0.00%	0.00%	0.00%	0.00%	5.81%	5.97%	5.76%	5.55%	5.04%
Enterprise Value to Invested Capital (EV/IC)	1.28	1.46	1.60	1.53	1.47	1.52	1.70	1.63	1.66	1.74	1.86
Enterprise Value to Revenue (EV/Rev)	3.50	4.02	3.91	3.74	3.58	3.69	4.17	4.04	4.12	4.32	4.57
Enterprise Value to EBITDA (EV/EBITDA)	10.57	12.03	360.42	358.16	252.46	257.55	12.37	12.36	12.72	13.29	14.29
Enterprise Value to EBIT (EV/EBIT)	11.79	13.38	0.00	0.00	0.00	0.00	13.66	13.71	14.11	14.64	15.66
Enterprise Value to NOPAT (EV/NOPAT)	14.81	16.79	0.00	0.00	0.00	0.00	18.06	17.71	18.22	18.95	20.43
Enterprise Value to Operating Cash Flow (EV/OCF)	15.82	19.04	19.20	19.24	17.98	17.34	18.84	17.61	17.39	18.81	20.66
Enterprise Value to Free Cash Flow (EV/FCFF)	14.76	17.36	16.05	16.47	15.20	14.85	17.80	17.26	17.72	20.15	23.22
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.89	0.85	0.94	0.90	0.82	0.75	0.68	0.65	0.61	0.57	0.56
Long-Term Debt to Equity	0.89	0.85	0.94	0.90	0.82	0.75	0.68	0.65	0.61	0.57	0.56
Financial Leverage	0.97	0.90	0.92	0.89	0.83	0.77	0.78	0.75	0.68	0.63	0.59
Leverage Ratio	2.39	2.31	2.32	2.29	2.22	2.16	2.15	2.10	2.04	1.97	1.93
Compound Leverage Factor	1.90	1.83	2.48	1.82	1.78	1.74	1.75	1.72	1.74	1.72	1.68
Debt to Total Capital	47.09%	46.02%	48.40%	47.25%	45.13%	42.96%	40.65%	39.52%	37.78%	36.32%	36.08%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	47.09%	46.02%	48.40%	47.25%	45.13%	42.96%	40.65%	39.52%	37.78%	36.32%	36.08%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	52.91%	53.98%	51.60%	52.75%	54.87%	57.04%	59.35%	60.48%	62.22%	63.68%	63.92%
Debt to EBITDA	3.93	3.89	110.91	112.41	79.01	74.29	2.99	3.02	2.92	2.81	2.85
Net Debt to EBITDA	3.81	3.65	106.13	107.78	75.25	70.37	2.87	2.92	2.78	2.67	2.58
Long-Term Debt to EBITDA	3.93	3.89	110.91	112.41	79.01	74.29	2.99	3.02	2.92	2.81	2.85
Debt to NOPAT	5.50	5.42	-86.51	-78.16	-88.59	-83.12	4.36	4.32	4.19	4.00	4.07
Net Debt to NOPAT	5.34	5.10	-82.78	-74.94	-84.38	-78.74	4.19	4.19	3.98	3.81	3.69
Long-Term Debt to NOPAT	5.50	5.42	-86.51	-78.16	-88.59	-83.12	4.36	4.32	4.19	4.00	4.07
Altman Z-Score	1.66	1.87	1.59	1.96	1.98	2.11	2.38	2.36	2.48	2.66	2.81
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.21	2.55	2.44	2.66	2.99	3.09	3.20	3.23	3.56	3.68	4.20
Quick Ratio	1.24	1.52	1.40	1.44	1.68	1.87	1.91	1.80	2.01	2.13	2.74
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	65	58	94	340	347	362	64	67	71	55	29
Operating Cash Flow to CapEx	2,421.72%	3,047.25%	2,305.98%	3,255.72%	2,128.83%	3,580.76%	2,128.76%	4,754.86%	3,443.51%	4,156.51%	1,777.75%
Free Cash Flow to Firm to Interest Expense	3.86	3.23	4.94	19.16	19.71	21.85	4.20	5.11	5.79	4.79	2.73
Operating Cash Flow to Interest Expense	3.39	3.07	3.11	2.71	3.55	4.31	4.38	4.17	5.68	5.68	5.75
Operating Cash Flow Less CapEx to Interest Expense	3.25	2.97	2.97	2.63	3.38	4.19	4.18	4.08	5.52	5.55	5.43
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.30	0.30	0.32	0.32	0.32	0.32	0.34	0.33	0.33	0.34	0.34
Accounts Receivable Turnover	7.57	7.61	7.36	7.45	7.40	6.85	6.55	6.75	6.90	6.55	6.13
Inventory Turnover	3.89	3.69	3.56	3.36	3.37	3.31	3.33	3.09	3.13	3.34	3.51
Fixed Asset Turnover	15.83	15.91	15.92	16.10	16.03	16.21	15.32	15.31	15.25	15.54	15.06
Accounts Payable Turnover	10.24	9.36	8.48	8.80	10.10	9.80	9.85	10.21	13.17	17.06	17.38
Days Sales Outstanding (DSO)	48.20	47.95	49.58	49.00	49.30	53.32	55.75	54.04	52.91	55.74	59.52
Days Inventory Outstanding (DIO)	93.93	98.95	102.60	108.62	108.38	110.38	109.61	118.11	116.47	109.13	103.86
Days Payable Outstanding (DPO)	35.63	39.00	43.04	41.49	36.12	37.23	37.06	35.74	27.72	21.39	21.00
Cash Conversion Cycle (CCC)	106.49	107.90	109.13	116.13	121.56	126.47	128.30	136.40	141.67	143.48	142.38
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	3,035	3,054	2,762	2,767	2,755	2,758	2,758	2,760	2,748	2,773	2,788
Invested Capital Turnover	0.37	0.36	0.39	0.39	0.39	0.39	0.41	0.40	0.40	0.40	0.41
Increase / (Decrease) in Invested Capital	-0.82	8.61	-290	-274	-280	-296	-3.73	-6.61	-7.08	15	31
Enterprise Value (EV)	3,879	4,452	4,411	4,225	4,036	4,180	4,690	4,501	4,573	4,827	5,197
Market Capitalization	2,480	3,100	3,112	2,953	2,833	3,038	3,603	3,437	3,573	3,858	4,259
Book Value per Share	$32.55	$34.06	$29.12	$29.79	$31.00	$32.26	$33.34	$33.67	$34.94	$36.20	$37.04
Tangible Book Value per Share	($32.69)	($31.50)	($28.63)	($27.84)	($26.63)	($25.31)	($24.03)	($23.35)	($22.48)	($21.24)	($19.94)
Total Capital	3,061	3,125	2,804	2,806	2,799	2,806	2,789	2,779	2,783	2,809	2,871
Total Debt	1,441	1,438	1,357	1,326	1,263	1,206	1,134	1,098	1,052	1,020	1,036
Total Long-Term Debt	1,441	1,438	1,357	1,326	1,263	1,206	1,134	1,098	1,052	1,020	1,036
Net Debt	1,399	1,352	1,299	1,271	1,203	1,142	1,087	1,064	1,000	969	938
Capital Expenditures (CapEx)	2.38	1.80	2.56	1.48	2.93	2.00	3.14	1.15	2.03	1.57	3.48
Debt-free, Cash-free Net Working Capital (DFCFNWC)	142	162	173	190	198	203	212	220	222	224	244
Debt-free Net Working Capital (DFNWC)	184	249	231	244	258	266	258	255	274	275	342
Net Working Capital (NWC)	184	249	231	244	258	266	258	255	274	275	342
Net Nonoperating Expense (NNE)	14	15	44	13	14	13	11	11	9.62	8.99	9.81
Net Nonoperating Obligations (NNO)	1,415	1,367	1,315	1,286	1,219	1,157	1,103	1,079	1,016	985	954
Total Depreciation and Amortization (D&A)	9.22	8.95	9.61	8.53	8.96	9.07	9.36	8.58	8.36	7.30	7.69
Debt-free, Cash-free Net Working Capital to Revenue	12.81%	14.64%	15.30%	16.81%	17.61%	17.87%	18.80%	19.80%	20.01%	20.01%	21.43%
Debt-free Net Working Capital to Revenue	16.64%	22.43%	20.49%	21.64%	22.94%	23.48%	22.93%	22.87%	24.65%	24.56%	30.03%
Net Working Capital to Revenue	16.64%	22.43%	20.49%	21.64%	22.94%	23.48%	22.93%	22.87%	24.65%	24.56%	30.03%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$1.02	$1.05	($4.82)	$1.07	$1.08	$1.07	$0.99	$0.98	$1.10	$1.23	$1.01
Adjusted Weighted Average Basic Shares Outstanding	49.80M	49.69M	49.89M	49.77M	49.69M	49.74M	49.76M	49.89M	49.65M	49.60M	49.70M
Adjusted Diluted Earnings per Share	$1.02	$1.04	($4.80)	$1.06	$1.07	$1.06	$0.98	$0.98	$1.09	$1.22	$1.00
Adjusted Weighted Average Diluted Shares Outstanding	50.27M	50.19M	49.89M	50.20M	50.08M	50.13M	50.18M	50.27M	50.00M	49.99M	50.08M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	49.53M	49.69M	49.69M	49.54M	49.62M	49.65M	49.92M	49.56M	49.41M	49.54M	49.41M
Normalized Net Operating Profit after Tax (NOPAT)	65	66	-197	66	67	66	60	61	64	70	60
Normalized NOPAT Margin	22.35%	24.13%	-68.81%	23.65%	23.44%	23.41%	21.79%	22.65%	22.55%	24.12%	20.21%
Pre Tax Income Margin	23.02%	24.72%	-104.78%	24.60%	24.59%	24.61%	24.30%	21.87%	25.25%	27.61%	24.94%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	4.92	4.80	-14.78	4.88	5.00	5.20	5.41	5.45	6.84	8.00	7.87
NOPAT to Interest Expense	3.81	3.71	-10.37	3.73	3.81	3.99	3.96	4.61	5.21	6.11	5.57
EBIT Less CapEx to Interest Expense	4.78	4.70	-14.92	4.79	4.83	5.08	5.21	5.36	6.67	7.86	7.55
NOPAT Less CapEx to Interest Expense	3.67	3.61	-10.50	3.64	3.65	3.87	3.75	4.52	5.05	5.98	5.25
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	23.97%	23.77%	-60.75%	-44.21%	-30.58%	-30.99%	11.94%	12.66%	18.35%	18.79%	24.00%

Frequently Asked Questions About Prestige Consumer Healthcare's Financials

When does Prestige Consumer Healthcare's financial year end?

According to the most recent income statement we have on file, Prestige Consumer Healthcare's fiscal year ends in March. Their fiscal year 2025 ended on March 31, 2025.

How has Prestige Consumer Healthcare's net income changed over the last 10 years?

Prestige Consumer Healthcare's net income appears to be on an upward trend, with a most recent value of $214.61 million in 2025, rising from $78.26 million in 2015. The previous period was $209.34 million in 2024. See Prestige Consumer Healthcare's forecast for analyst expectations on what’s next for the company.

What is Prestige Consumer Healthcare's operating income?

Prestige Consumer Healthcare's total operating income in 2025 was $336.78 million, based on the following breakdown:

Total Gross Profit: $634.46 million
Total Operating Expenses: $297.69 million

How has Prestige Consumer Healthcare revenue changed over the last 10 years?

Over the last 10 years, Prestige Consumer Healthcare's total revenue changed from $714.62 million in 2015 to $1.14 billion in 2025, a change of 59.2%.

How much debt does Prestige Consumer Healthcare have?

Prestige Consumer Healthcare's total liabilities were at $1.57 billion at the end of 2025, a 5.8% decrease from 2024, and a 22.2% decrease since 2015.

How much cash does Prestige Consumer Healthcare have?

In the past 10 years, Prestige Consumer Healthcare's cash and equivalents has ranged from $21.32 million in 2015 to $97.88 million in 2025, and is currently $97.88 million as of their latest financial filing in 2025.

How has Prestige Consumer Healthcare's book value per share changed over the last 10 years?

Over the last 10 years, Prestige Consumer Healthcare's book value per share changed from 12.01 in 2015 to 37.04 in 2025, a change of 208.5%.

Related Companies

This page (NYSE:PBH) was last updated on 6/12/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Prestige Consumer Healthcare (PBH) Financials

Frequently Asked Questions About Prestige Consumer Healthcare's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Prestige Consumer Healthcare (PBH) Financials

Annual Income Statements for Prestige Consumer Healthcare

Quarterly Income Statements for Prestige Consumer Healthcare

Annual Cash Flow Statements for Prestige Consumer Healthcare

Quarterly Cash Flow Statements for Prestige Consumer Healthcare

Annual Balance Sheets for Prestige Consumer Healthcare

Quarterly Balance Sheets for Prestige Consumer Healthcare

Annual Metrics And Ratios for Prestige Consumer Healthcare

Quarterly Metrics And Ratios for Prestige Consumer Healthcare

Frequently Asked Questions About Prestige Consumer Healthcare's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools